Alkem Laboratories, engaged in the pharmaceutical and nutraceutical business with global operations, reported steady financial results for Q2FY26.
Financial Highlights:
- Revenues increased 17.16% year-on-year to ₹4,001 crore from ₹3,415 crore.
- Total expenses rose 15.89% to ₹3,209 crore from ₹2,769 crore.
- Consolidated net profit grew 10.97% to ₹779 crore from ₹702 crore.
- Earnings per share improved 11.09% to ₹63.99 from ₹57.60.
The company experienced strong topline growth driven by robust volumes and new product launches, while effective cost management supported profit growth.
Outlook:
Alkem Laboratories aims to capitalize on increasing demand in domestic and international markets through portfolio expansion, enhanced manufacturing capabilities, and strategic partnerships. Focus on innovation, regulatory compliance, and expanding its presence in complex and specialty segments is expected to support sustainable growth.
For detailed financial analysis and updates, follow Alkem Laboratories Ltd on the AlphaStreet India News Channel.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.